210 related articles for article (PubMed ID: 36729640)
1. Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.
Li Y
J Obstet Gynaecol; 2023 Dec; 43(1):2171282. PubMed ID: 36729640
[TBL] [Abstract][Full Text] [Related]
2. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials.
Purwar R; Ranjan R; Pal M; Upadhyay SK; Kumar T; Pandey M
World J Surg Oncol; 2023 May; 21(1):157. PubMed ID: 37217940
[TBL] [Abstract][Full Text] [Related]
3. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.
Lin Q; Liu W; Xu S; Shang H; Li J; Guo Y; Tong J
BJOG; 2021 Feb; 128(3):485-493. PubMed ID: 32654312
[TBL] [Abstract][Full Text] [Related]
7. The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
Skelin M; Šarčević D; Lešin Gaćina D; Mucalo I; Dilber I; Javor E
J Chemother; 2023 Apr; 35(2):150-157. PubMed ID: 35550005
[TBL] [Abstract][Full Text] [Related]
8. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
[TBL] [Abstract][Full Text] [Related]
9. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Cheng H; Yang J; Liu H; Xiang Y
Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
[TBL] [Abstract][Full Text] [Related]
10. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
Elsea D; Muston D; Fan L; Mihai A; Meng Y; Kasle A; Monberg M
Target Oncol; 2023 Jul; 18(4):531-541. PubMed ID: 37233868
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy.
Rognoni C; Lorusso D; Costa F; Armeni P
Adv Ther; 2024 Apr; 41(4):1385-1400. PubMed ID: 38329713
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
Yang Y; Du N; Xie L; Jiang J; Mo J; Hong J; Mao D; Ng DM; Shi H
World J Surg Oncol; 2020 Jul; 18(1):151. PubMed ID: 32622363
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
[TBL] [Abstract][Full Text] [Related]
16. Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
Kaneko M
Ann Pharmacother; 2022 Jan; 56(1):27-34. PubMed ID: 33926263
[TBL] [Abstract][Full Text] [Related]
17. Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis.
Lee B; Chang SJ; Kwon BS; Son JH; Lim MC; Kim YH; Lee SW; Choi CH; Eoh KJ; Lee JY; Suh DH; Kim YB
PLoS One; 2023; 18(11):e0294647. PubMed ID: 37976295
[TBL] [Abstract][Full Text] [Related]
18. Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.
Pan YE; Hood A; Ahmad H; Altwerger G
Ann Pharmacother; 2023 Oct; 57(10):1162-1171. PubMed ID: 36651235
[TBL] [Abstract][Full Text] [Related]
19. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
[TBL] [Abstract][Full Text] [Related]
20. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
